Article Figures & Data
Figures
- FIGURE 1.
Images of SCLC patient showing thoracic and liver tumor involvement (arrows). (A) CT scan obtained before RIT shows multiple liver metastases. (B) Scintigraphy image (anterior view) obtained 7 d after injection of 131I-hapten shows targeting of thoracic and liver metastases.
- FIGURE 2.
(A) Scintigraphy image (posterior view) obtained 7 d after injection of 131I-hapten shows high bone marrow uptake in MTC patient. (B) MR image of same patient indicates bone marrow metastases (arrows).
- FIGURE 3.
Scintigraphy images (posterior view) illustrate distribution of 131I-hapten in MTC patient (A) and SCLC patient (B). Bone marrow uptake is higher in MTC patient.
Tables
Patient code Age (y) Sex Histopathology Location CEA (ng/mL) Prior treatments BsmAb (mg/m2) Hapten (GBq/m2) Morphologic response Biomarker response 01-16 49 M Rectum adenocarcinoma Pelvis 71 Su, C, R 75 1.8 Progression Progression 01-17 51 F Rectum adenocarcinoma Lung 50 Su, C 75 1.8 St (3 mo) St (3 mo) 01-18 59 M Colon adenocarcinoma Lung 499 Su, C 75 1.8 Progression Progression 01-19 47 M MTC Liver, bone 258 Su 75 1.8 St (12 mo+) ND* 01-20 36 M MTC Lung, bone 6 Su 75 1.8 St (12 mo+) St (12 mo+) 01-21 58 M MTC Lung, chest, bone 156 Su, R 75 1.8 St (6 mo) St (6 mo) 01-23 56 M MTC Neck, bone, lung, chest, liver 114 Su, R 75 1.8 St (3 mo) St (3 mo) 01-24 34 F Colon adenocarcinoma Lung, liver, pelvis 226 Su, C 40 1.1† Progression Progression 03-25 57 M SCLC Lung, liver 229 ND 75 2.3 St (3 mo) St (3 mo) 01-26 38 F MTC Neck, chest, lung, liver, kidney, bone 322 Su, C 75 1.8 Progression Progression 01-27 44 F MTC Abdomen 78 Su 75 1.8 St (12 mo+) ND* 01-28 56 H Rectum adenocarcinoma Chest, lung, pelvis 458 Su, C, R 40 2.3 Progression Progression 02-29 55 M Lung adenocarcinoma Lung 20 Su, C 75 1.8 Progression Progression 01-30 69 M SCLC Lung, chest 10 C, R 40 2.3 Progression Progression 03-31 66 M SCLC Lung, liver 14 C, R 40 2.3 Progression Progression 02-32 53 F Pleura adenocarcinoma Lung 14 C 40 2.3 Progression Progression 01-33 64 F MTC Neck, bone doubtful 11 Su, RIT 40 1.8 St (12 mo+) St (12 mo+) 03-34 49 M MTC Chest, bone 352 Su 40 1.8 Progression Progression 01-35 62 M Rectum adenocarcinoma Lung, bone, pelvis 25 Su, C, R 40 1.3† Progression Progression 01-36 48 F Colon adenocarcinoma Liver, abdomen 360 Su, C 40 2.9 St (6 mo) St (3 mo) 03-37 51 M MTC Neck, chest, bone ND Su 40 1.8 ND ND 01-38 55 F Rectum adenocarcinoma Lung, liver 8 Su, C, R 40 2.9 Progression Progression Patient code BsmAb (mg/m2) Group Activity level (GBq/m2) Injected activity (GBq) Grade Nadir (d) Duration of nadir (d) 01-16 75 A 1.8 3.0 II (WBC), I (platelets) 41, 31 ND, 11 01-17 75 A 1.8 3.0 II (WBC), I (platelets) 44, 31 8, 13 01-18 75 A 1.8 3.2 II (WBC), II (platelets) 43, 28 6, 8 02-29 75 A 1.8 2.5 I (platelets) 28 6 03-25 75 A 2.3 4.3 IV (WBC), III (platelets) 37, 27 3, 31 01-19 75 B 1.8 2.8 III (WBC), III (platelets) 41, 28 15, 28 01-20 75 B 1.8 3.1 III (WBC), III (platelets) 42, 29 6, 27 01-21 75 B 1.8 2.4 IV (WBC), III (platelets) 36, 23 13, 64 01-23 75 B 1.8 2.7 II (WBC), I (platelets) 41, 41 15, 15 01-26 75 B 1.8 2.6 I (WBC) 27 31 01-27 75 B 1.8 2.9 III (WBC), III (platelets) 35, 28 6, 13 01-24 40 A C 1.9 ND 01-28 40 A 2.3 3.9 0 01-30 40 A 2.3 4.3 II (WBC), II (platelets) 29, 29 8, 8 03-31 40 A 2.3 4.2 0 02-32 40 A 2.3 3.9 0 01-35 40 A C 2.2 0 01-36 40 A 2.9 5.5 III (WBC), II (platelets) 43, 35 8, 8 01-38 40 A 2.9 4.8 I (WBC) 43 ND 01-33 40 B 1.8 2.7 III (WBC), I (platelets) 44, 20 11, 14 03-34 40 B 1.8 2.6 IV (WBC), III (platelets) 30, 30 6, 6 03-37 40 B 1.8 2.6 ND Group A = non-MTC patients; WBC = white blood cells; ND = not done; Group B = MTC patients; C = compassionate treatment.
Patient no. BsmAb (mg/m2) HAHA (ng/mL) HAMA (ng/mL) Before RIT 1–2 mo after RIT 3 mo after RIT 6 mo after RIT Before RIT 1–2 mo after RIT 3 mo after RIT 6 mo after RIT 01-16 75 0 0 113 ND 1 0 0 ND 01-17 75 0 6 876 622 0 0 44 140 01-18 75 0 0 ND ND 0 0 ND ND 01-19 75 31 54 ND ND 0 0 ND ND 01-20 75 16 15 0 ND 0 0 0 ND 01-21 75 0 9 85 162 0 0 0 0 01-23 75 16 19 41 ND 0 0 0 ND 01-26 75 13 367 135 ND 0 0 0 ND 01-27 75 23 8 43 ND 0 0 0 ND 01-28 40 36 0 ND ND 0 0 ND ND 01-30 40 82 0 ND ND 0 0 ND ND 01-33 40 ND 0 ND ND 0 0 ND ND ND = not done.
Positive result was >74 ng/mL for HAMA and >100 ng/mL for HAHA.
BsmAb dose (mg/m2) Group of patients No. of patients No. of anatomic sites % of detected lesions 75 All 10 26 77% 75 Non-MTC 4 9 100% 75 MTC 6 17 65% 40 All 9 23 62% 40 Non-MTC 7 18 61% 40 MTC 2 5 80% Calculations were made on an anatomic-site basis.
Jump to section
Related Articles
Cited By...
- Pretargeting: A Path Forward for Radioimmunotherapy
- Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis
- Current Landscape in Clinical Pretargeted Radioimmunoimaging and Therapy
- Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and 90Y-DOTA
- "Catch-and-Release" Anti-Carcinoembryonic Antigen Monoclonal Antibody Leads to Greater Plasma and Tumor Exposure in a Mouse Model of Colorectal Cancer
- Pretargeted Imaging and Therapy
- Establishment of the In Vivo Efficacy of Pretargeted Radioimmunotherapy Utilizing Inverse Electron Demand Diels-Alder Click Chemistry
- Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial
- Phase II Trial of Anticarcinoembryonic Antigen Pretargeted Radioimmunotherapy in Progressive Metastatic Medullary Thyroid Carcinoma: Biomarker Response and Survival Improvement
- Convergent Potency of Internalized Gelonin Immunotoxins across Varied Cell Lines, Antigens, and Targeting Moieties
- Pretargeted 177Lu Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colonic Tumors in Mice
- An experimental and theoretical evaluation of the influence of pretargeting antibody on the tumor accumulation of effector
- Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting
- Pathology Underrates Colon Cancer Extranodal and Nodal Metastases; Ex vivo Radioimmunodetection Helps Staging
- Pretargeted Anti-Carcinoembryonic-Antigen Radioimmunotherapy for Medullary Thyroid Carcinoma
- Radioimmunotherapy of Solid Tumors: The Promise of Pretargeting Strategies Using Bispecific Antibodies and Radiolabeled Haptens